• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Exelixis Inc.

    3/26/26 6:23:12 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXEL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 12)


    Exelixis Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    30161Q104

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    30161Q104


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Exelixis Inc
    (b)Address of issuer's principal executive offices:

    1851 Harbor Bay Pkwy, Alameda, CA, 94502
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/26/2026
    Get the next $EXEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXEL

    DatePrice TargetRatingAnalyst
    1/8/2026$48.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2026$41.00Neutral → Underperform
    BofA Securities
    11/18/2025Peer Perform
    Wolfe Research
    11/3/2025Buy → Neutral
    Guggenheim
    10/21/2025$48.00Market Perform → Outperform
    Leerink Partners
    9/19/2025$40.00Equal Weight
    Barclays
    9/17/2025$40.00Equal Weight
    Barclays
    9/17/2025$47.00Buy
    Goldman
    More analyst ratings

    $EXEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Research and Development Aftab Dana was granted 52,018 shares, increasing direct ownership by 8% to 668,124 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    3/2/26 7:59:39 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP and General Counsel Hefti Brenda was granted 23,119 shares, increasing direct ownership by 24% to 119,631 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    3/2/26 7:59:26 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP and CFO Senner Christopher J. was granted 52,018 shares, increasing direct ownership by 5% to 1,028,110 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    3/2/26 7:59:32 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exelixis downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Exelixis from Overweight to Equal-Weight and set a new price target of $48.00

    1/8/26 8:39:35 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis downgraded by BofA Securities with a new price target

    BofA Securities downgraded Exelixis from Neutral to Underperform and set a new price target of $41.00

    1/5/26 8:47:51 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Exelixis

    Wolfe Research initiated coverage of Exelixis with a rating of Peer Perform

    11/18/25 8:22:21 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Exelixis Inc.

    SCHEDULE 13G/A - EXELIXIS, INC. (0000939767) (Subject)

    3/26/26 6:23:12 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Exelixis Inc.

    144 - EXELIXIS, INC. (0000939767) (Subject)

    2/17/26 6:47:14 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Exelixis Inc.

    10-K - EXELIXIS, INC. (0000939767) (Filer)

    2/10/26 4:32:29 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Johnson David Edward bought $1,187,235 worth of shares (27,532 units at $43.12) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    11/26/25 4:05:28 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    5/30/24 7:50:14 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    2/22/24 5:08:50 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

    9/21/23 4:37:02 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    7/15/22 4:38:40 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    9/20/21 3:53:29 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

    - Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference: Exelixis is scheduled to present at 1:10 p.m. ET / 10:10 a.m. PT on Tuesday, March 3 in Boston. Leerink Partners 2026 Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, March 10 in Miami. 2026 Citizens Life Sciences Conference: Exelixis is scheduled to present at 9:35 a.m. ET / 6:35 a.m. PT on Wednesday, March 11 in Miami. Barclays 28th Annual Global Healthcare Conference: Exel

    2/24/26 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

    – Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of $0.88 for the Fourth Quarter of 2025, $2.78 for the Fiscal Year 2025 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis deli

    2/10/26 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

    – The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results from the phase 3 STELLAR-303 pivotal trial, in which zanzalintinib in combination with atezolizumab improved median overall survival and significantly reduced the risk of death versus regorafenib in the intention-to-treat population – Exelixis, Inc. (NASDAQ:EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin

    2/2/26 8:00:00 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

    – Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, inclu

    8/29/25 5:47:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $EXEL
    Financials

    Live finance-specific insights

    View All

    Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

    – Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of $0.88 for the Fourth Quarter of 2025, $2.78 for the Fiscal Year 2025 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis deli

    2/10/26 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

    – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com a

    1/27/26 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    - Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on critical strategic priorities

    11/4/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

    SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

    5/8/24 4:11:20 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Exelixis Inc.

    SC 13G - EXELIXIS, INC. (0000939767) (Subject)

    2/13/24 9:19:48 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

    SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

    6/2/23 5:05:24 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care